Trusopt, Dorzolamide Newswire

Trusopt, Dorzolamide Newswire

Comprehensive Real-Time News Feed for Trusopt, Dorzolamide (generic).

Results 1 - 3 of 3 in Trusopt, Dorzolamide (generic)

  1. Topical dorzolamide-timolol beneficial in neovascular AMDRead the original story w/Photo

    Feb 26, 2016 | PhysOrg Weblog

    Topical dorzolamide hydrochloride-timolol appears to reduce central subfield thickness and subretinal fluid in eyes of patients with neovascular age-related macular degeneration and incomplete response to anti-vascular endothelial growth factor therapy, according to a study published online Feb. 25 in JAMA Ophthalmology . Jayanth Sridhar, M.D., from the Thomas Jefferson University in Philadelphia, and colleagues conducted a prospective single-arm interventional study involving patients with neovascular AMD and persistent macular edema despite fixed-interval intravitreous anti-VEGF therapy.

    Comment?

  2. DORZOLAMIDE (CAS 130693-82-2) Industry 2016 Global and Chinese Market Research ReportRead the original story

    Jan 21, 2016 | Emailwire.com

    WiseGuyReports.com adds 'Global and Chinese Dorzolamide Industry, 2016 Market Research Report' new report to its research database. The report spread across 150 pages with table and figures.

    Comment?

  3. Sylentis announces top-line results from Phase II study for RNAi drug in GlaucomaRead the original story w/Photo

    Oct 1, 2015 | EurekAlert!

    All bamosiran doses similarly reduced the intraocular pressure . In patients with a baseline IOP greater than or equal to 25 mm Hg, 1.125% bamosiran showed more efficacy The trial did not meet the secondary objective of demonstrating non-inferiority compared to timolol in the total patient population; however, bamosiran at dose 1.125% showed non-inferiority in patients with baseline IOP greater than or equal to 25 mm Hg Madrid, October 2nd, 2015: Sylentis, a pharmaceutical company of Grupo Zeltia , pioneer in research and development of new RNA interference -based therapies announced today top-line results of a dose-finding Phase II study, SYLTAG, for the novel RNAi therapeutic bamosiran in patients with open-angle glaucoma or ocular hypertension.

    Comment?